Actively Recruiting
Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Failure MSS Metastatic Colorectal Cancer.
Led by Ningbo Medical Center Lihuili Hospital · Updated on 2024-09-25
30
Participants Needed
1
Research Sites
155 weeks
Total Duration
On this page
Sponsors
N
Ningbo Medical Center Lihuili Hospital
Lead Sponsor
S
Shanghai Shengdi Pharmaceutical Co., Ltd
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn about Fruquintinib combined with Adebrelimab and high and low dose radiotherapy in the treatment of second-line and above failure MSS(microsatellite stability) metastatic colorectal cancer. The main question it aims to answer is: The efficacy and safety of Fruquintinib combined with Adebrelimab and high and low dose radiotherapy in the third line and beyond treatment of MSS metastatic colorectal cancer. Participants will receive the combination of Fruquintinib and Adebrelimab within 3 weeks after completion of high and low dose radiotherapy on metastases until disease progression or intolerable toxicity occurred.
CONDITIONS
Official Title
Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Failure MSS Metastatic Colorectal Cancer.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older, any gender
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
- Diagnosed with microsatellite stable metastatic colorectal cancer
- Disease progression after standard second-line treatment as per Chinese Society of Clinical Oncology guidelines
- At least one measurable tumor lesion according to RECIST 1.1 criteria
- Ability to follow the study protocol during the research period
- Signed informed consent form
You will not qualify if you...
- History of uncontrolled epilepsy, central nervous system disorders, or mental health conditions that may affect consent or medication adherence
- Presence of untreated other malignant tumors
- Blood and biochemical tests not meeting specified minimum levels (hemoglobin, neutrophil count, platelets, liver enzymes, bilirubin, creatinine, albumin)
- Serious active heart disease or recent myocardial infarction within 12 months
- Irreversible blood clotting problems or active major bleeding
- Active infections requiring antibiotics
- Allergic to any study drug ingredients
- Pregnant or breastfeeding women
- History of organ transplantation requiring immunosuppressive or long-term hormone therapy
- Autoimmune diseases
- Previous drug treatments that conflict with the study protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Kaitai Liu
Ningbo, Zhejiang, China, 315040
Actively Recruiting
Research Team
K
Kaitai Liu, doctor
CONTACT
S
Shuang Ye, master
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here